Parkinson Disease
📧 Sign up to get email alerts when something new happens for Parkinson Disease.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-25EMA Authorised: Hopledo (carbidopa monohydrate;levodopa) — Zambon SpA
Hopledo, a fixed-dose combination of carbidopa monohydrate and levodopa, has been authorised by the EMA for Parkinson disease. The marketing…
-
EMA approval · 2026-08-20EMA Authorised: Rivastigmine Hexal (rivastigmine) — Hexal AG
Rivastigmine Hexal has been authorised for dementia-related indications in the European market.
-
EMA approval · 2026-08-20EMA Authorised: Rivastigmine Sandoz (rivastigmine) — Sandoz GmbH
EMA authorised rivastigmine Sandoz for dementia indications, including Alzheimer disease and Parkinson disease.
-
EMA approval · 2026-08-20EMA Authorised: Rivastigmine 1 A Pharma (rivastigmine) — 1 A Pharma GmbH
EMA authorises rivastigmine 1 A Pharma for Alzheimer's disease, dementia, and Parkinson's disease.
-
FDA approval · 2026-08-18FDA Tentative Approval: CARBIDOPA AND LEVODOPA — Original Application (DR REDDYS LABS LTD)
Tentative approval for an original application of carbidopa and levodopa tablets (ANDA) by Dr. Reddy's Labs Ltd.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2026-08-03FDA Tentative Approval: CARBIDOPA AND LEVODOPA — Original Application (BIOCON PHARMA LIMITED)
FDA tentative approval for a generic CARBIDOPA AND LEVODOPA product (BIOCON PHARMA LIMITED) under ANDA 220119.
-
FDA approval · 2026-04-15FDA Approved: DATSCAN — Supplemental Application (Medi-Physics Inc. dba GE Healthcare.)
This is a supplemental FDA approval for DATSCAN (ioflupane I-123) as a dopamine transporter imaging agent. It helps in evaluating suspected …
-
EMA approval · 2026-04-07EMA Authorised: Neupro (rotigotine) — UCB Pharma S.A.
The EMA has authorised Neupro (rotigotine) by UCB Pharma S.A. for Restless legs syndrome and Parkinson's disease.
-
FDA approval · 2026-03-31FDA Approved: INBRIJA — Supplemental Application (Merz Pharmaceuticals, LLC)
FDA approved a supplemental application for INBRIJA (levodopa inhalation powder) submitted by Merz Pharmaceuticals, LLC.
-
FDA approval · 2026-03-19FDA Approved: CREXONT — Supplemental Application (Amneal Pharmaceuticals LLC)
The FDA approved a supplemental application for CREXONT (carbidopa and levodopa) filed by Amneal Pharmaceuticals LLC.
-
FDA approval · 2026-03-19FDA Approved: VYALEV — Supplemental Application (AbbVie Inc.)
FDA approved a supplemental application for VYALEV (foscarbidopa/foslevodopa) from AbbVie.
-
FDA approval · 2026-03-19FDA Approved: SINEMET — Supplemental Application (Organon LLC)
FDA approved a supplemental application for SINEMET (carbidopa/levodopa) submitted by Organon LLC.
-
FDA approval · 2026-03-19FDA Approved: DUOPA — Supplemental Application (AbbVie Inc.)
The FDA approved a supplemental application for DUOPA (carbidopa and levodopa) filed by AbbVie Inc.
-
FDA approval · 2026-03-19FDA Approved: CARBIDOPA, LEVODOPA, AND ENTACAPONE — Supplemental Application (Sandoz Inc)
FDA approved a supplemental application for the generic fixed-dose combination of carbidopa, levodopa, and entacapone by Sandoz Inc.
-
FDA approval · 2026-03-19FDA Approved: CARBIDOPA AND LEVODOPA — Supplemental Application (Zydus Pharmaceuticals USA Inc.)
FDA approved a supplemental application for Carbidopa and Levodopa submitted by Zydus Pharmaceuticals USA Inc., approving an amendment to th…
-
FDA approval · 2026-03-19FDA Approved: DHIVY — Supplemental Application (Avion Pharmaceuticals, LLC)
The FDA approved a supplemental application for DHIVY (carbidopa-levodopa) submitted by Avion Pharmaceuticals, LLC. This action updates the …
-
EMA approval · 2026-02-25EMA Authorised: DaTSCAN (ioflupane (123l)) — GE Healthcare B.V.
EMA authorised DaTSCAN, a radiopharmaceutical imaging agent (ioflupane I-123) by GE Healthcare B.V., for use in the diagnostic assessment of…
-
EMA approval · 2026-02-24EMA Authorised: Exelon (rivastigmine) — Novartis Europharm Limited
The European Medicines Agency authorised Exelon (rivastigmine) for dementia including Alzheimer's disease and Parkinson's disease, with Nova…
-
EMA approval · 2026-02-09EMA Authorised: Xadago (safinamide methanesulfonate) — Zambon SpA
The EMA authorised Xadago (safinamide methanesulfonate) for Parkinson disease; Zambon SpA is the marketing authorisation holder.
-
FDA approval · 2026-02-05FDA Approved: CARBIDOPA, LEVODOPA AND ENTACAPONE — Original Application (Alembic Pharmaceuticals Inc.)
The FDA approved the original application for a generic fixed-dose combination of carbidopa, levodopa, and entacapone for Parkinson's diseas…
-
EMA approval · 2026-01-16EMA Authorised: Rivastigmine Hexal (rivastigmine) — Hexal AG
Hexal AG's rivastigmine product has been authorized in the EU for dementia-related indications including Alzheimer's disease and Parkinson's…
-
EMA approval · 2026-01-16EMA Authorised: Rivastigmine Sandoz (rivastigmine) — Sandoz GmbH
The European Medicines Agency authorised Rivastigmine Sandoz (rivastigmine) for dementia indications, including Alzheimer's disease and Park…
-
EMA approval · 2026-01-16EMA Authorised: Rivastigmine 1 A Pharma (rivastigmine) — 1 A Pharma GmbH
The EMA authorised rivastigmine from 1 A Pharma GmbH for use in Alzheimer's disease, dementia, and Parkinson's disease.
-
EMA approval · 2025-12-09EMA Authorised: Inbrija (levodopa) — Merz Therapeutics GmbH
The EMA authorised Inbrija (levodopa) by Merz Therapeutics GmbH for Parkinson disease. This marks EU market authorisation for an inhaled lev…
-
FDA approval · 2025-12-05FDA Approved: AMANTADINE HYDROCHLORIDE — Supplemental Application (Patrin Pharma, Inc.)
FDA approved a supplemental application for amantadine hydrochloride submitted by Patrin Pharma, Inc.